However, when used as a single agent, trastuzumab is beneficial only in 15–30% of HER-2/neu breast cancer patients, which can be significantly increased to 50–80% by the addition of chemotherapeutic drugs [25]. The gene discussed is ERBB2; the disease is breast cancer.